poisar

Stocks · News reference

Biofrontera Q2 EPS $(0.05) Misses $(0.04) Estimate, Sales $12.003M Beat $10.500M Estimate

Aug 13, 2026, 12:54 PMBenzinga Newsdesk

Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 91.23 percent increase over losses of $(0.57) per share from the

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BFRI
Source
benzinga
Observed
Aug 13, 2026, 12:54 PM
Checked
Aug 13, 2026, 12:54 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Jul 3, 2026, 11:55 AMResearchandmarkets.Com

    Photodynamic Therapy Market: Durable Growth with a CAGR of 8.3% Through 2035

    The global photodynamic therapy (PDT) market is expected to grow at a CAGR of 8.3% from 2023 to 2035, driven by minimally invasive treatment demand, expanding applications in oncology and dermatology, and technological innovations. North America is projected to grow at 14% CAGR, while Europe currently holds 50% market share. Over 70 PDT therapies are under clinical development, with challenges including limited tissue penetration and high system costs.

    Read original at globenewswire-inc
    NVSGALDYBFRIBFRIW